Clinical Trial Update: Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas [Phase 1]

View source ↗

Summary

The document reports the completion of a Phase 1 study evaluating GO-203-2C given intravenously in patients with advanced solid tumors (including lymphomas).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• GO-203-2C (GO-203-2C)

Snippet

Sponsor: Genus Oncology, LLC | Conditions: Solid Tumors | Phase 1 | Status: COMPLETED